GNOM News and Press, Global X Genomics & Biotechnology ETF From 01/19/23

Summary Last year’s market volatility was driven primarily by uncertainty over inflation and interest rates. In last year’s downturn, technology stocks were at the epicenter of market volatility. After years of steady gains, investors now acknowledge that technology stocks...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

Summary The Global X Genomics & Biotechnology ETF tracks the Solactive Genomics Index. It invests in genomics and biotechnology companies. The fund is highly concentrated in one industry, which can negatively affect its performance. Increased regional exposure to Asia could be a...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material,  the Cleveland Clinic reported ....

Summary Healthcare stocks have remained in vogue through volatile markets, driven by increased interest in the sector during COVID-19. During a painful year for equity investors in 2022, healthcare stocks offered a pocket of relative stability. Global healthcare stocks ended the yea...

Summary How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector. How staff shortages in the health care sector may also impact investors. Health care managed to outperform the S&P 500 last yea...

Summary The top two mega themes in terms of global net inflows in 2022 were Climate Change-related themes and Big Data. The largest net outflows came from tech-heavy themes, led by Robotics & Automation. 2023 may bring a return to more normal markets driven by economics rather t...

RGNX is proceeding towards becoming a pillar of the gene therapy space for ocular diseases. However, it will need time to get there. The company is adequately funded for the journey. REGENXBIO Inc. ( RGNX ) is a developer of genetic treatments for eye diseases. Data ...

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to advance Belapectin towards other indications such ...

Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years. Now may be a good time to initiate a position with earnings coming soon. As I look at price charts at the end of the week for potential buys or shorts I notice...